Setting New Standards for Therapeutic Laser Innovation
Theralase® therapeutic laser systems have received full clearance by all major regulatory agencies for adjunctive use in pain therapy. Its effectiveness as a low level laser therapy (LLLT) medical device has been demonstrated through successful patient treatments in healthcare clinics around the world, supported by evidence established through over 4,000 clinical studies. An example of this evidence was a clinical study ("Laser Therapy Applications for Chronic Joint Pain") submitted to the FDA by Theralase® Technologies to demonstrate the application of laser therapy for chronic joint pain. This randomized placebo controlled clinical trial was completed with the objective of evaluating the Theralase® LLLT medical device as an adjunctive modality to standard treatment for knee pain using chiropractic techniques. The data obtained in the study clearly demonstrated that the Theralase® therapeutic laser provided significant relief and improvement in all of the primary evaluation criteria from chronic pain associated with knee disorders.
Theralase® superpulsed 905 nanometer (nm) near infrared and 660 nanometer (nm) visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure (MPE) tolerance for tissue. Each treatment needs to be customized for every patient to ensure that they are receiving the optimal dosage of laser energy. To achieve this, Theralase® cool laser therapy systems employ customizable pre-programmed treatment protocols that adjust using individual patients' physical characteristics and biometric information to meet patients' needs. Using superposed laser technology, Theralase® systems are able to penetrate deeper (up to 5 inches).
Theralase® TLC-2000 Series includes hard case, 2 pairs of protective glasses and Operation Manuals